The pandemic launched Abbott to the front lines of the most disruptive healthcare event in our lifetime as the company developed a portfolio of COVID-19 tests to help tackle the virus and get life back to normal. Now, with vaccine production ramping up and virus rates falling across much of the U.S., Abbott remains strong. The company is forecasting earnings per share (EPS) of $5.00, over 35% earnings growth in 2021. This growth is on top of the already strong base Abbott achieved in 2020. How is the company doing it? Through its diversified business model. 'We've got an exciting base business,' said Abbott President and CEO Robert Ford during the company's fourth quarter earnings call. 'We've got great portfolios, really strong brands, rich pipelines [and] a strong leadership position.' Market Leader Across Businesses Abbott is a leader in multiple markets, with standout cardiovascular products, diabetes care technology, diagnostics, neuromodulation devices and nutritional products, as well as branded generic medicines in developing markets. While COVID-19 testing certainly was a significant driver for Abbott in 2020 — with the company delivering more than 400 million COVID-19 tests since the pandemic's start — it wasn't the only growth driver. In fact, three of Abbott's four major businesses delivered positive sales growth despite shelter-in-place orders spurred by the pandemic and halts to non-essential travel and medical procedures. This growth helped Abbott achieve the upper-end of its original full-year 2020 EPS guidance of $3.65, despite the pandemic.